Dec 1 (Reuters) - Anavex Life Sciences Corp:
* ANAVEX®2–73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS, SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE
* KEY SECONDARY ENDPOINT CDR-SB ALSO MET, DEMONSTRATING STATISTICALLY SIGNIFICANT RESULTS
* PLAN TO MEET WITH REGULATORY AUTHORITIES TO DETERMINE NEXT STEPS
* MET PRIMARY ENDPOINTS AND REDUCED CLINICAL DECLINE ON GLOBAL COGNITIVE AND FUNCTIONAL SCALES OVER 48 WEEKS Source text for Eikon: Further company coverage: